{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:00Z","timestamp":1790743740551,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"DOI":"10.7759\/cureus.42847","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T13:25:20Z","timestamp":1690982720000},"source":"Crossref","is-referenced-by-count":3,"title":["Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes"],"prefix":"10.7759","author":[{"given":"Salman J","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Asjad Tauheed","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Fatima","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the global burden of disease study 2021","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","unstructured":"GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the global burden of disease study 2021. Lancet Haematol. 2023, 10.1016\/s2352-3026(23)00118-7","journal-title":"Lancet Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004123221504","article-title":"Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea","volume":"322","author":"Rodgers GP","year":"1990","unstructured":"Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990, 322:1037-45. 10.1056\/NEJM199004123221504","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L-glutamine in sickle cell disease","volume":"379","author":"Niihara Y","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J, et al.. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018, 379:226-35. 10.1056\/NEJMoa1715971","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga KI","year":"2017","unstructured":"Ataga KI, Kutlar A, Kanter J, et al.. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017, 376:429-39. 10.1056\/NEJMoa1611770","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky E","year":"2019","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, et al.. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019, 381:509-19. 10.1056\/NEJMoa1903212","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/175133-advancements-in-sickle-cell-disease-scd-treatment-a-review-of-novel-pharmacotherapies-and-their-impact-on-patient-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:47Z","timestamp":1707508967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/175133-advancements-in-sickle-cell-disease-scd-treatment-a-review-of-novel-pharmacotherapies-and-their-impact-on-patient-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.42847","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,2]]}}}